Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesThe effects of an olmesartan medoxomil–based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
The Journal of Clinical Hypertension, 07/01/09
Kereiakes DJ et al. – An olmesartan medoxomil (OM)-based treatment algorithm effectively lowers blood pressure (BP) in an elderly pt population throughout 24-hr dosing interval without compromising tolerability.
Methods- Study of the effect of OM ± hydrochlorothiazide (HCTZ) on mean 24-hr ambulatory BP, mean seated cuff (Se)BP, and SeBP goal achievement in hypertensive pts age ≥65 yrs
- After 2- to 3-wk placebo run-in, OM 20 mg, uptitrated to 40 mg, then added HCTZ 12.5 mg to 25 mg stepwise at 3-wk intervals if SeBP remained ≥120/70 mm Hg
- Primary endpoint: change from baseline in mean 24-hr ambulatory systolic BP
- At study end, mean 24-hr ambulatory BP decreased by 25.7/12.3 mm Hg (150 pts) and mean SeBP by 25.4/10.5 mm Hg (176 pts)
- Drug-related treatment-emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), in 11.8% of pts
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
New Anticoagulants for Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 09/15/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Atherosclerosis, 10/07/09
Sponsor
Article Search
Sponsor
Sponsor